Alemtuzumab in kidney-transplant recipients.
Summary of "Alemtuzumab in kidney-transplant recipients."
Over the past decade, the use of induction therapy in organ-transplant recipients to intensify immunosuppression during the peritransplantation period has contributed to a reduction in early rejection rates and graft loss in the first year after transplantation. It is now common practice to select from among available induction therapies on the basis of risk-benefit considerations for the individual patient. As of 2008, induction agents were administered in 82% of kidney recipients. These agents were administered less often in lung (57%), heart (47%), and liver (26%) recipients; such recipients usually received less potent agents that do not deplete T cells.(1) Induction . . .
Affiliation
From the Divisions of Transplant Surgery (J.F.M.) and Infectious Diseases (J.A.F.), Massachusetts General Hospital, Boston.
Journal Details
This article was published in the following journal.
Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 1968-9
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21591949
- DOI: http://dx.doi.org/10.1056/NEJMe1103002
Medical and Biotech [MESH] Definitions
Living Donors
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Histocompatibility Testing
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Immunoglobulins, Intravenous
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Kidney Papillary Necrosis
A complication of kidney diseases characterized by cell death involving KIDNEY PAPILLA in the KIDNEY MEDULLA. Damages to this area may hinder the kidney to concentrate urine resulting in POLYURIA. Sloughed off necrotic tissue may block KIDNEY PELVIS or URETER. Necrosis of multiple renal papillae can lead to KIDNEY FAILURE.
Kidney Cortex
The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL.
PubMed Articles
Alemtuzumab in kidney-transplant recipients.
Sirolimus-based immunosuppression for treatment of cutaneous warts in kidney transplant recipients.
Dermatological complications, especially skin infections, are very common following organ transplantation, and result in a lot of distress in the recipient. Herpes zoster, herpes simplex, and human pa...
Transplantation: Alemtuzumab induction is safe for renal transplant recipients.
Mutations in the UL97 gene are the most common mechanism of human cytomegalovirus resistance to ganciclovir in transplant recipients. In this study, UL97 fragments were amplified and sequenced in 70 C...
BACKGROUND.: Induction agents have been shown to reduce the rate of acute rejection. They have not been clearly shown to improve graft and patient survival. METHODS.: United Network for Organ Sharing...
Clinical Trials
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppre...
The Study of Long-term Deterioration of Kidney Transplants.
This study is being done to create a kidney transplant database with information from many transplant centers for the purpose of studying ways to help improve transplant outcomes and the c...
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
The study is being done to compare the safety and effects (good and bad) of three different combinations of immunosuppression drugs used by kidney transplant recipients while also looking...
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
Acumulating data suggest that thrapeutic drug therapeutic may optimize efficacity and tolerance of MMF. It could guarantee better exposure to the drug in the first 3 months and then minimi...
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Transplant rejection occurs when a patient's body does not recognize the new organ and attacks it. Patients who have kidney transplants must take drugs to prevent transplant rejection. Ale...
